靶向炎症小体治疗神经系统疾病
本文综述炎症小体在中枢神经系统稳态与损伤中的调控机制,汇总其在阿尔茨海默病、多发性硬化、脑损伤、卒中、癫痫、帕金森病和肌萎缩侧索硬化等疾病中的激活证据,并批判性讨论抑制炎症小体组分治疗神经系统疾病的前景与潜在局限。
要点
- 炎症小体激活促进IL-1β、IL-18分泌及细胞焦亡,与多种CNS疾病发生进展相关。
- 多种抑制炎症小体激活及信号的化合物在临床前模型中显示治疗效力。
- 靶向炎症小体治疗神经系统疾病的前景与潜在局限仍需批判性评估。
核心结论
- 炎症小体激活是多种常见免疫介导和退行性中枢神经系统疾病的机制基础之一。
- 抑制炎症小体组分的治疗策略在临床前模型中显示治疗效力,但其前景与潜在局限需批判性讨论。
研究设计与样本
- 综述文章,阐述中枢神经系统稳态与组织损伤中炎症小体激活的调控机制。
主要发现
- 炎症小体介导IL-1β和IL-18等促炎细胞因子的加工与分泌,并诱导焦亡这种促炎性细胞死亡形式。
- 炎症小体激活与阿尔茨海默病、多发性硬化、脑损伤、卒中、癫痫、帕金森病和肌萎缩侧索硬化的发生与进展相关。
- 越来越多抑制炎症小体激活及信号的药理化合物在上述疾病的临床前模型中显示治疗效力。
临床怎么用
- 关注炎症小体作为神经系统疾病治疗靶点的临床前证据,但需认识其向临床转化的潜在局限。
局限性
- 综述指出靶向炎症小体组分的治疗策略存在潜在局限,需批判性讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammasomes are multimeric protein complexes that can sense a plethora of microbe- and damage-associated molecular signals. They play important roles in innate immunity and are key regulators of inflammation in health and disease. Inflammasome-mediated processing and secretion of proinflammatory cytokines such as interleukin (IL) 1β and IL-18 and induction of pyroptosis, a proinflammatory form of cell death, have been associated with the development and progression of common immune-mediated and degenerative central nervous system (CNS) diseases such as Alzheimer disease, multiple sclerosis, brain injury, stroke, epilepsy, Parkinson disease, and amyotrophic lateral sclerosis. A growing number of pharmacological compounds inhibiting inflammasome activation and signaling show therapeutic efficacy in preclinical models of the aforementioned disease conditions. Here, we illustrate regulatory mechanisms of inflammasome activation during CNS homeostasis and tissue injury. We highlight the evidence for inflammasome activation as a mechanistic underpinning in a wide range of CNS diseases and critically discuss the promise and potential limitations of therapeutic strategies that aim to inhibit the inflammasome components in neurological disorders. ANN NEUROL 2021;90:177-188.
引用
- Lünemann JD, Malhotra S, Shinohara ML, et al. Targeting Inflammasomes to Treat Neurological Diseases. Ann Neurol. 2021. PMID: 34219266. doi:10.1002/ana.26158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。